Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations
American Journal of Preventive Cardiology · 2026-12 · 30 · 101735
DOI: 10.1016/j.ajpc.2026.101735 ↗Kurz gefasst
Leitlinie in der Zeitschrift American Journal of Preventive Cardiology, 2026-12. Verfasst von Deen L Garba und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sports Cardiology Program, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Mar…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Coronary artery disease (CAD) is the leading cause of exercise-related sudden cardiac death in athletes older than 35 years, and dyslipidemia is one of its principal modifiable drivers. The 2026 ACC/AHA/Multisociety Guideline on the Management of Blood Cholesterol introduces several advances directly relevant to athletes, including restored LDL-C treatment targets, universal lipoprotein(a) [Lp(a)] measurement, the PREVENT-ASCVD risk equations, expanded options for selective coronary artery calcium (CAC) scoring, and a more aggressive approach to lipid-lowering therapy (LLT). However, sports cardiology guidelines and consensus statements offer important caveats that must be reconciled with these general-population recommendations: existing risk calculators, including PREVENT, do not reliably estimate cardiovascular risk in athletes, and routine CAC scoring is not recommended in athletes at low calculated risk. This commentary compares and contrasts general-population dyslipidemia recommendations with athlete-specific guidance from contemporary sports cardiology consensus documents, highlights recent evidence on Lp(a), wearable-derived training load, and risk score performance across the physical activity spectrum, and proposes a five-step clinical framework, refined to reflect athlete-specific risk stratification, for dyslipidemia evaluation and management in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sports Cardiology Program, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zitieren
APA
Garba, D. L., Zahid, S., Blumenthal, R. S., & Barouch, L. A. (2026). Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations. American Journal of Preventive Cardiology, 30, 101735. https://doi.org/10.1016/j.ajpc.2026.101735
Vancouver
Garba DL, Zahid S, Blumenthal RS, Barouch LA. Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations. American Journal of Preventive Cardiology. 2026;30:101735. doi:10.1016/j.ajpc.2026.101735
BibTeX
@article{Garba2026,
author = {Garba, Deen L and Zahid, Sohail and Blumenthal, Roger S and Barouch, Lili A},
title = {Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations},
journal = {American Journal of Preventive Cardiology},
year = {2026},
volume = {30},
pages = {101735},
doi = {10.1016/j.ajpc.2026.101735}
}
EUVIMED